Overview
- Investigators at the SCAI 2026 meeting in Montreal on Thursday and Friday reported real‑world links between tirzepatide and better outcomes after coronary stenting (PCI) and transcatheter aortic valve replacement (TAVR).
- In a matched PCI cohort of 1,281 people with type 2 diabetes, tirzepatide users had a 62% lower risk of death than those on dulaglutide and fewer major events such as heart attacks, heart failure flare‑ups, and dangerous heart rhythms.
- The TAVR analysis in patients with obesity showed higher one‑year event‑free survival with tirzepatide, while non‑users had a 54% higher risk of hospitalization for acute heart failure and 44% more major cardiovascular events.
- Researchers saw no significant differences after TAVR in ischemic stroke, heart attack, or acute kidney injury, suggesting the observed benefits did not come with clear safety trade‑offs in these endpoints over one year.
- Both studies used TriNetX electronic health records with propensity matching, so authors urged randomized trials to confirm benefit, clarify when to start therapy, identify who benefits most, and test durability beyond one year.